[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Andrew Caravello, DO @andrewcaravello on x 1092 followers
Created: 2025-07-22 18:14:59 UTC
💉 The Deployment Engine: How $MRK West Point Expansion May Plug Directly into $NWBO ’s Immune OS
What if Merck’s $1B vaccine infrastructure isn’t just about pandemics or infectious disease?
What if it’s about cancer?
Merck’s West Point campus in Pennsylvania isn’t just massive, it’s purpose-built for industrial-grade syringe filling, packaging, and formulation. Recent expansions include:
•B63, a facility approved in 2019 for large-scale pre-filled syringe output.
•B63A, a sister facility completed by KeyPlants, capable of XX million pre-filled syringes annually.
•And now, a new expansion adding XXXXXXX sq ft to boost vaccine manufacturing and support sterile operations, including conjugate platforms like Prevnar.
Here’s where it gets interesting.
In The Silent Bomb, we showed how Mayo Clinic tested Merck’s vaccines (Prevnar 13® and Pneumovax® 23) intratumorally, alongside mature dendritic cells and cryoablation, essentially a functional preview of the NWBO DCVax-Direct architecture.
And we know from NWBO’s 10-K that a Material Transfer Agreement (MTA) is already in place for a “booster agent” from a large pharmaceutical company.
Now zoom out:
•Merck controls both the agent (Prevnar) and the fill-finish infrastructure (West Point). •These syringes are already manufactured under cGMP conditions, in single-dose format, and at industrial scale. •And these exact formats, conjugate vaccines in pre-filled syringes, were used clinically in Mayo’s DC trials and produced no safety signal.
🔄 That means if NWBO selects Prevnar or Pneumovax as V-class boosters for DCVax-Direct, Merck doesn’t need to build anything.
The production system is already running.
The cold-chain logistics are validated.
The regulatory filings for format and manufacturing have long been in place.
And that’s why West Point matters.
It turns DCVax-Direct from a scientific candidate into a distributable immunologic system, one with a fully functional, GMP-aligned, plug-in booster already backed by human trial precedent.
🧠Think about the implications:
•NWBO develops, licenses, and deploys the immune engine. •Merck supplies the injectable boosters, already filled, labeled, and validated under SI XX. •Flaskworks generates the autologous DC batches. •And West Point pumps the fuel.
In this configuration, the immune stack becomes not just modular, but industrial.
It becomes scalable.
And suddenly, a biotech once dismissed as “aspirational” may now be sitting on the only frictionless, regulatory-compliant, real-world ready OS for programmable immune therapy.
$NWBO $MRK $MDCX $LLY $AZN $ABBV #Flaskworks #Prevnar #BoosterLogic #WestPoint #ProgrammableMedicine #SI87 #MHRA #DCVax #OncologyOS #Keytruda #PrecisionOncology #CancerVaccine #GMP #VaccineManufacturing #CellTherapy
XXXXX engagements
Related Topics $1b os $nwbo $mrk stocks healthcare